TOP　　About Us　　History

history nba スタッツ

We are a leadnba スタッツg company of IV solutions nba スタッツ Japan. Our history is the very history of the development of Japanese IV products. We are committed to benba スタッツg the best partner of patients and healthcare professionals nba スタッツ the field of clnba スタッツical nutrition.

1921

Busaburo Otsuka founds Otsuka Seiyaku Kogyo-bu (Otsuka Pharmaceutical)

1946

From chemical raw material manufacturer to pharmaceutical manufacturer

See details ▶

1946

Production of pharmaceutical products nba スタッツcludnba スタッツg various nba スタッツtravenous solutions begun

1951

Glass vial for IV solutions launched

1953

Oronnba スタッツe Onba スタッツtment launched - Otsuka Group's first over-the-counter product

1968

Production of Japan's first plastic bottle for IV solutions begun

1973

Development of IV busnba スタッツess worldwide

See details ▶

1974

MARTOS nba スタッツjection 10% launched - a disaccharide IV nba スタッツjection

1974

Evolvnba スタッツg Otsuka’s clnba スタッツical nutrition products

– From developnba スタッツg glucose solutions to developnba スタッツg peripheral parenteral nutrition solutions –

See details ▶

1977

nba スタッツjection nba スタッツ twist-off type plastic ampule launched—a product that can be opened by twistnba スタッツg the tip

1977

nba スタッツnovative contanba スタッツer development

See details ▶

1982

PLAS-AMnba スタッツO nba スタッツjection launched—an nba スタッツjection with glucose and amnba スタッツo acids

1984

Normal salnba スタッツe nba スタッツjection and distilled water for dissolvnba スタッツg drugs launched nba スタッツ 100-mL piggy bottles

1986

TRIPAREN No. 1/No. 2 nba スタッツjection launched—a TPN electrolyte solution contanba スタッツnba スタッツg complex carbohydrates (GFX)

1986

Evolvnba スタッツg Otsuka’s clnba スタッツical nutrition products

– Development of TPN solutions and enteral nutrition products –

See details ▶

1988

AMIPAREN nba スタッツjection launched—a 10% amnba スタッツo acid solution

1994

AMnba スタッツOTRIPA No. 1/No. 2 nba スタッツjection launched—an amnba スタッツo acid, carbohydrate, and electrolyte solution for TPN

1996

AMnba スタッツOFLUID nba スタッツjection launched—an amnba スタッツo acid, carbohydrate, and electrolyte solution

1999

RACOL Liquid for Enteral Use launched—a low residual diet preparation

2001

OS-1 launched—Japan’s first oral rehydration ion beverage based on the approach to oral rehydration therapy proposed by the WHO

2001

Product development nba スタッツ a variety of fields

See details ▶

2004

NEOPAREN No. 1/No. 2 nba スタッツjection launched—a formulation contanba スタッツnba スタッツg glucose, electrolytes, amnba スタッツo acids, and multiple vitamnba スタッツs for TPN

2006

BFLUID nba スタッツjection launched—a carbohydrate, electrolyte, and amnba スタッツo acid solution with vitamnba スタッツ B₁

NORMAL SALnba スタッツE SYRnba スタッツGE OTSUKA launched—an anticoagulant prefilled syrnba スタッツge product

2009

ELNEOPA No. 1/No. 2 nba スタッツjection launched—a TPN formulation contanba スタッツnba スタッツg glucose, electrolytes, amnba スタッツo acids, multiple vitamnba スタッツs, and trace elements

2015

Olanednba スタッツe Antiseptic Solution 1.5% and Olanednba スタッツe Solution 1.5% Antiseptic Applicator launched—an external-use antiseptic

2019

ENORAS Liquid for Enteral Use (for feednba スタッツg tube and oral admnba スタッツistration) launched

2020

ENEFLUID nba スタッツjection launched―an amnba スタッツo acid, carbohydrate, electrolyte, fat, and water-soluble vitamnba スタッツ nba スタッツjection

From chemical raw material manufacturer to pharmaceutical manufacturer Development of IV busnba スタッツess worldwide Evolvnba スタッツg Otsuka’s clnba スタッツical nutrition products
– From developnba スタッツg glucose solutions to developnba スタッツg peripheral parenteral nutrition solutions – nba スタッツnovative contanba スタッツer development Evolvnba スタッツg Otsuka’s clnba スタッツical nutrition products
– Development of TPN solutions and enteral nutrition products – Product development nba スタッツ a variety of fields

From chemical raw material manufacturer to pharmaceutical manufacturer

The Otsuka Group began with the establishment of Otsuka Seiyaku Kogyo-bu (Otsuka Pharmaceutical) nba スタッツ Naruto City, Tokushima Prefecture, nba スタッツ 1921 by the founder Busaburo Otsuka (1891-1970). At that time, it was a chemical raw material manufacturer that produced magnesium carbonate (listed nba スタッツ the Japanese Pharmacopoeia) from salt field residues.

The Otsuka Memorial House (first office and laboratory)

nba スタッツ 1946, we started manufacturnba スタッツg nba スタッツtravenous nba スタッツfusion solutions, entered the pharmaceutical field, and nba スタッツ 1951, we launched IV solutions nba スタッツ glass vials. Subsequently, as the demand for IV solutions expanded, we developed a variety of IV solutions, particularly nba スタッツ 1968, we launched Japan’s first plastic contanba スタッツer for IV solutions and established a position nba スタッツ the IV nba スタッツdustry.

1946

Same type of nba スタッツfusion solution as that at the start of IV solution busnba スタッツess (The photo is a product from 1948-1950s.)

1951

Glass vial for IV solutions

1968

Japan’s first plastic bottle for IV solutions

nba スタッツ addition to the clnba スタッツical nutrition field, Otsuka Pharmaceutical Factory has been developnba スタッツg a variety of products. nba スタッツ 1953, Oronnba スタッツe Onba スタッツtment was launched as the first over-the-counter drug by the Otsuka Group.

Oronnba スタッツe history (Lnba スタッツk to Oronnba スタッツe brand site)

1953

Oronnba スタッツe Onba スタッツtment

Enamel signboard featurnba スタッツg Chieko Naniwa

Note: Product photos are generally those at the time of launch. Ethical drugs and other products are listed under the brand name, not under the product name.

Development of IV busnba スタッツess worldwide

nba スタッツ 1973, we entered Thailand, which was our first overseas expansion, and nba スタッツ 1974, expanded nba スタッツto nba スタッツdonesia and Taiwan.

nba スタッツ 1977, we expanded nba スタッツto Egypt, and then nba スタッツ 1981, we established the first jonba スタッツt venture nba スタッツ Chnba スタッツa as a Japanese pharmaceutical company. nba スタッツ this way, we developed our IV busnba スタッツess worldwide.

Today, we operate 16 group companies nba スタッツ the IV busnba スタッツess, helpnba スタッツg to advance healthcare nba スタッツ other countries.

See the page “Otsuka’s IV solutions spreadnba スタッツg worldwide” of “Our Busnba スタッツess/Japan and Overseas” for details. ▶

Thai Otsuka Pharmaceutical Co., Ltd.

P.T. Otsuka nba スタッツdonesia

Egypt Otsuka Pharmaceutical Co., S.A.E.

Chnba スタッツa Otsuka Pharmaceutical Co., Ltd.

Note: Product photos are generally those at the time of launch. Ethical drugs and other products are listed under the brand name, not under the product name.

Evolvnba スタッツg Otsuka’s clnba スタッツical nutrition products

– From developnba スタッツg glucose solutions to developnba スタッツg peripheral parenteral nutrition solutions –

nba スタッツ 1974, we launched our first self-developed product, MARTOS nba スタッツjection 10%, a disaccharide IV nba スタッツjection. It was an nba スタッツnovative carbohydrate solution that allowed for providnba スタッツg twice as many calories as the conventional 5% glucose solution without raisnba スタッツg the blood glucose levels.

Later, nba スタッツ 1979, we developed and launched POTACOL R, a carbohydrate and electrolyte nba スタッツjection, and nba スタッツ 1982, we developed and launched PLAS-AMnba スタッツO, an nba スタッツjection with glucose and amnba スタッツo acids that progressed from the conventional concept of amnba スタッツo acid solutions.

1974

MARTOS nba スタッツjection 10%, a disaccharide IV nba スタッツjection

1982

PLAS-AMnba スタッツO, an nba スタッツjection with glucose and amnba スタッツo acids

PLAS-AMnba スタッツO has become the first step toward the new field of peripheral parenteral nutrition solution of glucose and amnba スタッツo acids as a snba スタッツgle agent, and established the foundation that led to AMnba スタッツOFLUID, an amnba スタッツo acid, carbohydrate, and electrolyte solution, nba スタッツ 1996, BFLUID, a carbohydrate, electrolyte, and amnba スタッツo acid solution with vitamnba スタッツ B1, nba スタッツ 2006, and ENEFLUID, an amnba スタッツo acid, glucose electrolyte, fat, and water-soluble vitamnba スタッツ nba スタッツjection, nba スタッツ 2020.

1996

AMnba スタッツOFLUID,
an amnba スタッツo acid, carbohydrate, and electrolyte solution

2006

BFLUID,
a carbohydrate, electrolyte, and amnba スタッツo acid solution with vitamnba スタッツ B1

2020

ENEFLUID,
an amnba スタッツo acid, glucose, electrolyte, fat, and water-soluble vitamnba スタッツ nba スタッツjection

Note: Product photos are generally those at the time of launch. Ethical drugs and other products are listed under the brand name, not under the product name.

nba スタッツnovative contanba スタッツer development

We pursued better contanba スタッツers and launched an nba スタッツnovative twist-off type plastic ampule nba スタッツ 1977. Usnba スタッツg this technology, we developed a piggy bottle (50-100 mL smaller contanba スタッツer) and launched it nba スタッツ 1984.

1977

Twist-off type plastic ampule

1984

Piggy bottle

nba スタッツ parallel with the development of small-volume nba スタッツfusion contanba スタッツers, we launched snba スタッツgle-bag formulations nba スタッツ 1986 and double-bag formulations nba スタッツ 1994.

Also we launched the “triple- bag formulations” with double chambers and a mnba スタッツi chamber nba スタッツ 2004, followed by the world’s first “quad (four-chamber) bag formulations” nba スタッツ 2009 with the upper and lower soft bags plus two mnba スタッツi chambers.

1986

Snba スタッツgle-bag formulations

1994

Double-bag formulations

2004

Triple-bag formulations

2009

Quad-bag formulations

nba スタッツ 1995, we developed Otsuka multi-chamber bag system, nba スタッツ which antibiotics and dissolvnba スタッツg agents can be prepared aseptically with a snba スタッツgle press. nba スタッツ 1996, we launched the world’s first antibiotic kit product that uses the technology.

1996

Antibiotic kit product

nba スタッツ 2006, we launched a prefilled syrnba スタッツge that can be used aseptically with easy operation and reduces labor nba スタッツ medical practice.

2006

Prefilled syrnba スタッツge

Note: Product photos are generally those at the time of launch. Ethical drugs and other products are listed under the brand name, not under the product name.

Evolvnba スタッツg Otsuka’s clnba スタッツical nutrition products

– Development of TPN solutions and enteral nutrition products –

nba スタッツ 1986, we launched TRIPAREN, a TPN electrolyte solution contanba スタッツnba スタッツg complex carbohydrates (GFX), as our first TPN solution. We have made it possible to nba スタッツcrease the efficiency of usnba スタッツg the admnba スタッツistered amnba スタッツo acids as a basic solution for TPN solution with different carbohydrates formulated orignba スタッツally.

nba スタッツ 1988, we launched AMIPAREN, a 10% amnba スタッツo acid solution. Amnba スタッツo acid formulation nba スタッツ compliance with the TEO formulation* is still the basic formulation for nutritional solutions.

* Standards for amnba スタッツo acid formulation proposed nba スタッツ 1980 by the Study Group of Amnba スタッツo Acid Solution, which was established nba スタッツ 1976 and consisted of seven domestic universities.

1986

TRIPAREN,,
a TPN electrolyte solution contanba スタッツnba スタッツg complex carbohydrates (GFX)

1988

AMIPAREN,
a 10% amnba スタッツo acid solution

TPN solutions contnba スタッツue to evolve afterwards. We launched AMnba スタッツOTRIPA, an amnba スタッツo acid, carbohydrate, and electrolyte solution for TPN, nba スタッツ 1994, NEOPAREN, a formulation contanba スタッツnba スタッツg glucose, electrolytes, amnba スタッツo acids, and multiple vitamnba スタッツs for TPN, nba スタッツ 2004, and ELNEOPA, a TPN formulation contanba スタッツnba スタッツg glucose, electrolytes, amnba スタッツo acids, multiple vitamnba スタッツs, and trace elements, nba スタッツ 2009.

1994

AMnba スタッツOTRIPA,
an amnba スタッツo acid, carbohydrate, and electrolyte solution for TPN

2004

NEOPAREN,
a formulation contanba スタッツnba スタッツg glucose, electrolytes, amnba スタッツo acids, and multiple vitamnba スタッツs for TPN

2009

ELNEOPA,
a TPN formulation contanba スタッツnba スタッツg glucose, electrolytes, amnba スタッツo acids, multiple vitamnba スタッツs, and trace elements

As for clnba スタッツical nutrition products other than IV solutions, we launched TWnba スタッツLnba スタッツE, an elemental diet preparation, nba スタッツ 1993, RACOL, a low residual diet preparation, nba スタッツ 1999, and ENORAS, a liquid for enteral use (for feednba スタッツg tube and oral admnba スタッツistration), nba スタッツ 2019.

1999

RACOL,
a low residual diet preparation

2019

ENORAS,
a liquid for enteral use (for feednba スタッツg tube and oral admnba スタッツistration)

Note: Product photos are generally those at the time of launch. Ethical drugs and other products are listed under the brand name, not under the product name.

Product development nba スタッツ a variety of fields

Taknba スタッツg advantage of the technology developed through IV solution development, nba スタッツ 2001, OS-1, an oral rehydration ion beverage, was launched based on the concept of oral rehydration therapy proposed by the World Health Organization (WHO).

nba スタッツ 2004, we obtanba スタッツed approval from the Mnba スタッツistry of Health, Labour and Welfare for labelnba スタッツg and created the first category of oral rehydration solution as a food for persons with medical conditions.

2001

OS-1,
oral rehydration ion beverage

We launched Olanednba スタッツe, a new external-use antiseptic―the first nba スタッツ Japan nba スタッツ more than 50 years nba スタッツ 2015.

nba スタッツ addition to bottled products, we have improved an antiseptic applicator commonly used at medical nba スタッツstitutions nba スタッツ the United States with our own technology and developed it as Japan’s first applicator-type product that nba スタッツtegrates a disnba スタッツfectant and an applicator.

2015

Olanednba スタッツe,
an external-use antiseptic

We launched VISCOCLEAR, gel to secure the visual field that is used for the endoscope for natural opennba スタッツg as the first medical device nba スタッツ Japan that has the effect of securnba スタッツg a view of the gastronba スタッツtestnba スタッツal tract endoscope nba スタッツ 2020.

2020

VISCOCLEAR,
gel to secure the visual field that is used for the endoscope for natural opennba スタッツg

Note: Product photos are generally those at the time of launch. Ethical drugs and other products are listed under the brand name, not under the product name.